Chia YL - Search Results

1

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.

Jayne D, Rovin B, Mysler EF, Furie RA, Houssiau FA, Trasieva T, Knagenhjelm J, Schwetje E, Chia YL, Tummala R, Lindholm C. Jayne D, et al. Among authors: chia yl. Ann Rheum Dis. 2022 Apr;81(4):496-506. doi: 10.1136/annrheumdis-2021-221478. Epub 2022 Feb 10. Ann Rheum Dis. 2022. PMID: 35144924 Free PMC article. Clinical Trial.

2

Exposure-response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus.

Chia YL, Santiago L, Wang B, Kuruvilla D, Wang S, Tummala R, Roskos L. Chia YL, et al. Rheumatology (Oxford). 2021 Dec 1;60(12):5854-5862. doi: 10.1093/rheumatology/keab176. Rheumatology (Oxford). 2021. PMID: 33629110 Clinical Trial.

3

Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus.

Chia YL, Zhang J, Tummala R, Rouse T, Furie RA, Morand EF. Chia YL, et al. Rheumatology (Oxford). 2022 May 5;61(5):1900-1910. doi: 10.1093/rheumatology/keab704. Rheumatology (Oxford). 2022. PMID: 34528084 Free PMC article. Clinical Trial.

4

Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus.

Chia YL, Tummala R, Mai TH, Rouse T, Streicher K, White WI, Morand EF, Furie RA. Chia YL, et al. J Clin Pharmacol. 2022 Sep;62(9):1094-1105. doi: 10.1002/jcph.2054. Epub 2022 May 21. J Clin Pharmacol. 2022. PMID: 35352835 Free PMC article.

5

Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus.

Almquist J, Kuruvilla D, Mai T, Tummala R, White WI, Tang W, Roskos L, Chia YL. Almquist J, et al. Among authors: chia yl. J Clin Pharmacol. 2022 Sep;62(9):1106-1120. doi: 10.1002/jcph.2055. Epub 2022 May 21. J Clin Pharmacol. 2022. PMID: 35383948 Free PMC article.

6

Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.

Bruce IN, Nami A, Schwetje E, Pierson ME, Rouse T, Chia YL, Kuruvilla D, Abreu G, Tummala R, Lindholm C. Bruce IN, et al. Among authors: chia yl. Lancet Rheumatol. 2021 Feb;3(2):e101-e110. doi: 10.1016/S2665-9913(20)30342-8. Epub 2020 Nov 20. Lancet Rheumatol. 2021. PMID: 38279367

7

Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants.

Cheung TT, Mai TH, Chia YL, Yap DYH, Lee CH, Chen CC, Huang Y, Jin Y, Johnston J, Werkström V, Yao Y, Ge X, Zheng W. Cheung TT, et al. Among authors: chia yl. Drug Des Devel Ther. 2023 Jan 26;17:209-218. doi: 10.2147/DDDT.S392155. eCollection 2023. Drug Des Devel Ther. 2023. PMID: 36726737 Free PMC article. Clinical Trial.

8

Relationship Between Benralizumab Exposure and Efficacy for Patients With Severe Eosinophilic Asthma.

Chia YL, Yan L, Yu B, Wang B, Barker P, Goldman M, Roskos L. Chia YL, et al. Clin Pharmacol Ther. 2019 Aug;106(2):383-390. doi: 10.1002/cpt.1371. Epub 2019 Mar 22. Clin Pharmacol Ther. 2019. PMID: 30661249 Free PMC article. Clinical Trial.

9

Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia.

Kuruvilla D, Chia YL, Balic K, Yao NS, Kreitman RJ, Pastan I, Li X, Standifer N, Liang M, Tseng CM, Faggioni R, Roskos L. Kuruvilla D, et al. Among authors: chia yl. Br J Clin Pharmacol. 2020 Jul;86(7):1367-1376. doi: 10.1111/bcp.14250. Epub 2020 Mar 16. Br J Clin Pharmacol. 2020. PMID: 32077130 Free PMC article.

10

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, Mehdi A, O'Reilly SM, Hamm JT, Barrett-Lee PJ, Cocquyt V, Sideras K, Young DE, Zhao C, Chia YL, Hoch U, Hannah AL, Perez EA; NKTR-102 Study Group. Awada A, et al. Among authors: chia yl. Lancet Oncol. 2013 Nov;14(12):1216-25. doi: 10.1016/S1470-2045(13)70429-7. Epub 2013 Oct 4. Lancet Oncol. 2013. PMID: 24095299 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

26 results

Search Page

Filters